Convenia (cefovecin sodium) is an FDA-Approved, injectable antimicrobial indicated for the treatment of canine skin infections (secondary superficial pyoderma, abscesses, and wounds) caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). It also is indicated in feline skin infections (wounds and abscesses) caused by susceptible strains of Pasteurella multocida.
Convenia is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).
Convenia is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.
Convenia should be administered as a single subcutaneous injection of 3.6 mg/lb (8 mg/kg) body weight. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete. The decision for a second injection for any individual dog should take into consideration such factors as progress toward clinical resolution, the susceptibility of the causative organisms, and the integrity of the dog’s host-defense mechanisms. Therapeutic drug concentrations after the first injection are maintained for 7 days for S. intermedius infections and for 14 days for S. canis (Group G) infections. Maximum treatment should not exceed 2 injections.
Convenia should be administered as a single, one-time subcutaneous injection at a dose of 3.6 mg/lb (8 mg/kg) body weight. After an injection of Convenia, therapeutic concentrations are maintained for approximately 7 days for Pasteurella multocida infections.
A sample of the lesion should be obtained for culture and susceptibility testing prior to beginning antimicrobial therapy. Once results become available, continue with appropriate therapy. If acceptable response to treatment is not observed, or if no improvement is seen within 3 to 4 days, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.
Convenia may persist in the body for up to 65 days. The effect of remaining concentrations of cefovecin on any subsequent antimicrobial therapies has not been determined. Fluoroquinolone and aminoglycoside antimicrobials have been reported to be compatible with cephalosporin antimicrobial agents.1
|Dose||3.6 mg/lb (8 mg/kg) subcutaneous injection|
|Frequency|| A single injection provides up to 14 days of treatment|
Occasionally, a repeat dose may be needed to ensure complete clinical resolution in dogs
|Notes||Product is light-sensitive and should be stored in the original carton and refrigerated when not in use.|
|Animal Weight||5 lb||10 lb||15 lb||20 lb||40 lb||80 lb|
|Convenia Volume||0.23 ml||0.45 ml||0.67 ml||0.90 ml||1.80 ml||3.60 ml|
Store the powder and the reconstituted product in the original carton, refrigerated at 2° to 8° C (36° to 46° F). Use the entire contents of the vial within 56 days of reconstitution. PROTECT FROM LIGHT. After each use it is important to return the unused portion back to the refrigerator in the original carton. As with other cephalosporins, the color of the solution may vary from clear to amber at reconstitution and may darken over time. If stored as recommended, solution color does not adversely affect potency.
Convenia is contraindicated in dogs and cats with known allergy to cefovecin or to β-lactam (penicillins and cephalosporins) group antimicrobials. Anaphylaxis has been reported with the use of this product in foreign market experience. If an allergic reaction or anaphylaxis occurs, Convenia should not be administered again and appropriate therapy should be instituted. Anaphylaxis may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Adverse reactions may require prolonged treatment due to the prolonged systemic drug clearance (65 days).
Not for use in humans. Keep this and all drugs out of reach of children. Consult a physician in case of accidental human exposure. For subcutaneous use in dogs and cats only. Antimicrobial drugs, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. To minimize the possibility of allergic reactions, those handling such antimicrobials, including cefovecin, are advised to avoid direct contact of the product with the skin and mucous membranes.
Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection isunlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistantanimal pathogens.
Lethargy, Anorexia/Decreased Appetite, Vomiting, Diarrhea, Blood in Feces, Flatulence, Increased Borborygmi.
Vomiting, Diarrhea, Anorexia/Decreased Appetite, Lethargy, Hyper/Acting Strange, Inappropriate Urination.